This is what you can look forward to now that the Bioharp is in XMDC's possession (from the 12/21/2009 PR):
1. Finalize the end product design relating to the device and software. This has already been agreed upon by management and we will look to have the finished product very shortly to begin sales to the veterinary, equine, and horticulture sectors.
2. Secure our manufacturing contracts so we can meet our anticipated needs of 20-30,000 units per month for 2010. (This number could rise dramatically based on our current contract conversations with several health organizations globally.)
3. Amend our KFDA application
with the adjustments made to the device and software. Expected approval is within six-eight weeks for anticipated sales in South Korea.
4. Initialize programs with several cancer centers, early disease detection clinics, and children's hospitals in the U.S. to establish the necessary criteria for submission to the FDA.
5. Establish our training standards to create jobs wherein Certified BioHarp technicians can be deployed to hospitals, clinics, and healthcare groups in the U.S. and other countries. This will assist the company in creating opportunities for individuals to be trained and gain successful employment for years to come, either as an employee or for outside healthcare companies.
6. Work closely with several global universities that have expressed a desire to utilize the BioHarp in their studies of crops and plant growth, thereby establishing the BioHarp's efficacy in assisting nations in their food and fuel productivity through proper scanning using the BioHarp device.
7. Focus on completing the company's audited financials within the first quarter of 2010 in order to gain a listing on a higher exchange. The company is currently interviewing auditors in order to accomplish the audit in a timely manner.
Our goal is to focus on immediate sales as well as planning the future of the company wherein we capitalize on the many opportunities the BioHarp can bring to XTend Medical," stated Mr. Paul D. Lisenby, CEO of XTend Medical.
